Communication of the meeting of Transparency Council No. 11/2026 on 16 March 2026 with resolutions

We invite you to read minutes of the meeting of Transparency Council No. 11/2026 on 16 March 2026 during which the following resolutions were adopted:

1. At its meeting on 16 March 2026, the Transparency Council adopted position No. 31/2026 on the evaluation of the drug Bupropion Neuraxpharm (bupropion hydrochloride) for the indication: treatment of major depressive episodes
2. At its meeting on 16 March 2026, the Transparency Council adopted position No. 32/2026 on the evaluation of the drug Hympavzi (marstacimab) under Drug Program B.15 “Prevention of bleeding in children and adults with hemophilia A and B (ICD-10: D66, D67)”
3. At its meeting on 16 March 2026, the Transparency Council adopted position No. 33/2026 on the appropriateness of granting reimbursement approvals for food products for special nutritional purposes—MSUD Anamix Infant, MSUD Anamix Junior, MSUD Anamix Junior LQ, MSUD Gel, MSUD Cooler, MSUD Express, and MSUD Lophlex LQ—for various indications
4. At its meeting on 16 March 2026, the Transparency Council adopted opinion No. 33/2026 on the draft program “Healthy Heart of the Lublin Region – Comprehensive Cardiac Rehabilitation Program” (Lublin Province)
5. At its meeting on 16 March 2026, the Transparency Council adopted opinion No. 34/2026 on the inclusion of medicinal products containing the active ingredients ramipril and indapamide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics
6. At its meeting on 16 March 2026, the Transparency Council adopted opinion No. 35/2026 on the coverage of reimbursement for medicinal products containing the active ingredient sirolimus for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., rubbery pigmented lesions
7. At its meeting on 16 March 2026, the Transparency Council adopted opinion No. 36/2026 on the coverage of reimbursement for medicinal products containing the active ingredient sirolimus for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics, i.e., rubbery pigmented lesions
8. At its meeting on 16 March 2026, the Transparency Council adopted opinion No. 37/2026 on the inclusion of medicinal products containing the active ingredient budesonide in the reimbursement program for indications, dosages, or routes of administration that differ from those specified in the Summary of Product Characteristics

Transparency Council meeting protocol >>